Nexplanon (Etonogestrel)

Etonogestrel, the active ingredient in Nexplanon, is a progestin presented as a 68 mg subdermal implant for subcutaneous use. It provides long‑acting hormonal contraception to prevent pregnancy in women of reproductive age.

GNH USA supplies Nexplanon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nexplanon, containing etonogestrel, is used within the hormonal contraceptive pathway to prevent unintended pregnancy.

- Prevention of pregnancy: delivers continuous contraception for up to three years after insertion.

Nexplanon may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Irregular vaginal bleeding or spotting - Amenorrhea (absence of periods) - Headache - Weight gain - Acne or skin changes - Breast tenderness

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Severe allergic reaction (anaphylaxis) - Infection at the insertion site - Ectopic pregnancy if contraceptive failure occurs - Hormone‑sensitive tumor growth

Before Nexplanon insertion, clinicians should evaluate patient history and counsel on potential risks. - Contraindications: Do not use in women with known thromboembolic disorders or active breast cancer. - Screening: Assess for liver disease or hormone‑sensitive conditions. - Bleeding patterns: Counsel that irregular bleeding is common during the first months. - Pregnancy: Discontinue immediately if pregnancy is confirmed. - Storage: Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nexplanon can interact with other medicines that affect hormone metabolism or clotting risk.

Major Interactions (Avoid): - Rifampin, carbamazepine, phenytoin: enzyme inducers that may reduce contraceptive efficacy. - St. John's wort: herbal inducer that can lower etonogestrel levels. - Efavirenz: antiretroviral that may decrease hormone concentrations.

Moderate Interactions (Monitor Closely): - Ketoconazole, itraconazole: antifungals that may increase hormone levels. - Combined hormonal contraceptives: concurrent use may raise clotting risk. - Anticoagulants: monitor for altered bleeding tendencies.